Exosomes have been discovered in 1983 (Pan and Johnstone, 1983) and are defined as 40-100 nm extracellular vesicles originating from the fusion of multi-vesicular bodies, also referred to as late endosomes, with the plasma membrane. They are known to mediate cell-to-cell communication as they can carry proteins, nucleic acids, and lipids, providing through that cargo a paracrine effect to the recipient tissues or cells (Mitchell et al., 2019). Thus, stem cell-derived exosomes have been used as a shuttle in cell-free therapies for the treatment of different conditions such as kidney diseases (Dorronsoro and Robbins, 2013) or osteoarthritis (Zhang et al., 2019). Among stem cell types, perinatal tissue-derived stem cells are a good alternative to embryonic stem cells as they are obtained without major ethical issues since they come from discarded fetal annexa, but the use of their secretome is still not common as there are over 30 clinical trials using perinatal tissue-derived stem cells but less than 10 trials using their derived exosomes (https://clinicaltrials.gov/). Among the perinatal tissues, the amniotic membrane is a good source of mesenchymal stem cells (Alviano et al., 2007) but the use of these stem cells or their derived exosomes is not as spread out as the other stem cells types, although they have the same properties and their secretome is as rich in growth and anti-apoptotic factors (An et al., 2017).